Accentia licenses steroid nasal spray from Collegium to market in United States for allergic rhinitis

By E. Janene Geiss

Philadelphia, Dec. 6 - Accentia Biopharmaceuticals, Inc. announced Tuesday that it has entered into an exclusive license with Collegium Pharmaceuticals, Inc. to market in the United States a branded intranasal steroid intended for the symptoms of seasonal and perennial allergic rhinitis.

This product will be marketed by Accentia's specialty pharmaceutical division, Teamm Pharmaceuticals. This license will expand Accentia's pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market, according to a company news release.

Collegium plans to file a Supplemental New Drug Application in 2006 for the nasal spray formulation, officials said.

"The intranasal steroid market in the U.S. represents approximately $2.7 billion in annual sales. The primary competition for this market has been prescription nonsedating oral antihistamine products, which have annual sales in excess of $4 billion ... We anticipate that over the next several years many of the non-sedating antihistamines will migrate to the over-the-counter marketplace. This anticipated shift in the market may benefit growth in the intranasal steroid prescription market," said Michael Heffernan, president of Collegium, in the release.

The company's respiratory product portfolio includes the CRSFungal Profile, a non-invasive test to diagnose chronic sinusitis and differentiation of it from allergic rhinitis. It also said it expects to launch MDTurbo, a patented delivery device for metered-dose inhalers used to treat asthma and chronic obstructive pulmonary disease. And its pipeline includes an intranasal antifungal for chronic sinusitis under an Investigational New Drug Application, officials said.

Accentia is a Tampa, Fla., biopharmaceutical company focused on the development and commercialization of late-stage clinical products for respiratory disease and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.